Selected research
Industry Research
Third Party Clinical Testing Industry Research Report 2026
Market perspective
The global Third Party Clinical Testing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Third Party Clinical Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Third Party Clinical Testing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Third Party Clinical Testing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Third Party Clinical Testing include Labcorp, IQVIA, PAREXEL International Corporation, ICON Plc, Charles River Laboratories, Syneos Health, PPD (Pharmaceutical Product Development), Medpace and WuXi AppTec, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Third Party Clinical Testing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Third Party Clinical Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Third Party Clinical Testing Market by Company
Labcorp
IQVIA
PAREXEL International Corporation
ICON Plc
Charles River Laboratories
Syneos Health
PPD (Pharmaceutical Product Development)
Medpace
WuXi AppTec
Kingmed
Dian Diagnostics
Adicon Clinical Laboratories
Kindstar
DaAn Gene
Berry Genomics
Frontage Holdings
Centre Testing International
Shanghai Labway Clinical Laboratory
Third Party Clinical Testing Segment by Type
Biochemical Tests
Immunity Tests
Routine Blood Tests
Others
Third Party Clinical Testing Segment by Application
Personal
Enterprise
Third Party Clinical Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Third Party Clinical Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Third Party Clinical Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Third Party Clinical Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Third Party Clinical Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biochemical Tests
- Immunity Tests
- Routine Blood Tests
- Others
Applications
- Personal
- Enterprise
Companies covered
- Labcorp
- IQVIA
- PAREXEL International Corporation
- ICON Plc
- Charles River Laboratories
- Syneos Health
- PPD (Pharmaceutical Product Development)
- Medpace
- WuXi AppTec
- Kingmed
- Dian Diagnostics
- Adicon Clinical Laboratories
- Kindstar
- DaAn Gene
- Berry Genomics
- Frontage Holdings
- Centre Testing International
- Shanghai Labway Clinical Laboratory
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Third Party Clinical Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Biochemical Tests
- 2.2.3 Immunity Tests
- 2.2.4 Routine Blood Tests
- 2.2.5 Others
- 2.3 Third Party Clinical Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Personal
- 2.3.3 Enterprise
- 2.4 Assumptions and Limitations
3 Third Party Clinical Testing Breakdown Data by Type
- 3.1 Global Third Party Clinical Testing Historic Market Size by Type (2021-2026)
- 3.2 Global Third Party Clinical Testing Forecasted Market Size by Type (2027-2032)
4 Third Party Clinical Testing Breakdown Data by Application
- 4.1 Global Third Party Clinical Testing Historic Market Size by Application (2021-2026)
- 4.2 Global Third Party Clinical Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Third Party Clinical Testing Market Perspective (2021-2032)
- 5.2 Global Third Party Clinical Testing Growth Trends by Region
- 5.2.1 Global Third Party Clinical Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Third Party Clinical Testing Historic Market Size by Region (2021-2026)
- 5.2.3 Third Party Clinical Testing Forecasted Market Size by Region (2027-2032)
- 5.3 Third Party Clinical Testing Market Dynamics
- 5.3.1 Third Party Clinical Testing Industry Trends
- 5.3.2 Third Party Clinical Testing Market Drivers
- 5.3.3 Third Party Clinical Testing Market Challenges
- 5.3.4 Third Party Clinical Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Third Party Clinical Testing Players by Revenue
- 6.1.1 Global Top Third Party Clinical Testing Players by Revenue (2021-2026)
- 6.1.2 Global Third Party Clinical Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global Third Party Clinical Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Third Party Clinical Testing Head Office and Area Served
- 6.4 Global Third Party Clinical Testing Players, Product Type & Application
- 6.5 Global Third Party Clinical Testing Manufacturers Established Date
- 6.6 Global Third Party Clinical Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Third Party Clinical Testing Market Size (2021-2032)
- 7.2 North America Third Party Clinical Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Third Party Clinical Testing Market Size by Country (2021-2026)
- 7.4 North America Third Party Clinical Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Third Party Clinical Testing Market Size (2021-2032)
- 8.2 Europe Third Party Clinical Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Third Party Clinical Testing Market Size by Country (2021-2026)
- 8.4 Europe Third Party Clinical Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Third Party Clinical Testing Market Size (2021-2032)
- 9.2 Asia-Pacific Third Party Clinical Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Third Party Clinical Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Third Party Clinical Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Third Party Clinical Testing Market Size (2021-2032)
- 10.2 South America Third Party Clinical Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Third Party Clinical Testing Market Size by Country (2021-2026)
- 10.4 South America Third Party Clinical Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Third Party Clinical Testing Market Size (2021-2032)
- 11.2 Middle East & Africa Third Party Clinical Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Third Party Clinical Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Third Party Clinical Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Labcorp
- 12.1.1 Labcorp Company Information
- 12.1.2 Labcorp Business Overview
- 12.1.3 Labcorp Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.1.4 Labcorp Third Party Clinical Testing Product Portfolio
- 12.1.5 Labcorp Recent Developments
- 12.2 IQVIA
- 12.2.1 IQVIA Company Information
- 12.2.2 IQVIA Business Overview
- 12.2.3 IQVIA Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.2.4 IQVIA Third Party Clinical Testing Product Portfolio
- 12.2.5 IQVIA Recent Developments
- 12.3 PAREXEL International Corporation
- 12.3.1 PAREXEL International Corporation Company Information
- 12.3.2 PAREXEL International Corporation Business Overview
- 12.3.3 PAREXEL International Corporation Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.3.4 PAREXEL International Corporation Third Party Clinical Testing Product Portfolio
- 12.3.5 PAREXEL International Corporation Recent Developments
- 12.4 ICON Plc
- 12.4.1 ICON Plc Company Information
- 12.4.2 ICON Plc Business Overview
- 12.4.3 ICON Plc Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.4.4 ICON Plc Third Party Clinical Testing Product Portfolio
- 12.4.5 ICON Plc Recent Developments
- 12.5 Charles River Laboratories
- 12.5.1 Charles River Laboratories Company Information
- 12.5.2 Charles River Laboratories Business Overview
- 12.5.3 Charles River Laboratories Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.5.4 Charles River Laboratories Third Party Clinical Testing Product Portfolio
- 12.5.5 Charles River Laboratories Recent Developments
- 12.6 Syneos Health
- 12.6.1 Syneos Health Company Information
- 12.6.2 Syneos Health Business Overview
- 12.6.3 Syneos Health Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.6.4 Syneos Health Third Party Clinical Testing Product Portfolio
- 12.6.5 Syneos Health Recent Developments
- 12.7 PPD (Pharmaceutical Product Development)
- 12.7.1 PPD (Pharmaceutical Product Development) Company Information
- 12.7.2 PPD (Pharmaceutical Product Development) Business Overview
- 12.7.3 PPD (Pharmaceutical Product Development) Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.7.4 PPD (Pharmaceutical Product Development) Third Party Clinical Testing Product Portfolio
- 12.7.5 PPD (Pharmaceutical Product Development) Recent Developments
- 12.8 Medpace
- 12.8.1 Medpace Company Information
- 12.8.2 Medpace Business Overview
- 12.8.3 Medpace Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.8.4 Medpace Third Party Clinical Testing Product Portfolio
- 12.8.5 Medpace Recent Developments
- 12.9 WuXi AppTec
- 12.9.1 WuXi AppTec Company Information
- 12.9.2 WuXi AppTec Business Overview
- 12.9.3 WuXi AppTec Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.9.4 WuXi AppTec Third Party Clinical Testing Product Portfolio
- 12.9.5 WuXi AppTec Recent Developments
- 12.10 Kingmed
- 12.10.1 Kingmed Company Information
- 12.10.2 Kingmed Business Overview
- 12.10.3 Kingmed Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.10.4 Kingmed Third Party Clinical Testing Product Portfolio
- 12.10.5 Kingmed Recent Developments
- 12.11 Dian Diagnostics
- 12.11.1 Dian Diagnostics Company Information
- 12.11.2 Dian Diagnostics Business Overview
- 12.11.3 Dian Diagnostics Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.11.4 Dian Diagnostics Third Party Clinical Testing Product Portfolio
- 12.11.5 Dian Diagnostics Recent Developments
- 12.12 Adicon Clinical Laboratories
- 12.12.1 Adicon Clinical Laboratories Company Information
- 12.12.2 Adicon Clinical Laboratories Business Overview
- 12.12.3 Adicon Clinical Laboratories Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.12.4 Adicon Clinical Laboratories Third Party Clinical Testing Product Portfolio
- 12.12.5 Adicon Clinical Laboratories Recent Developments
- 12.13 Kindstar
- 12.13.1 Kindstar Company Information
- 12.13.2 Kindstar Business Overview
- 12.13.3 Kindstar Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.13.4 Kindstar Third Party Clinical Testing Product Portfolio
- 12.13.5 Kindstar Recent Developments
- 12.14 DaAn Gene
- 12.14.1 DaAn Gene Company Information
- 12.14.2 DaAn Gene Business Overview
- 12.14.3 DaAn Gene Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.14.4 DaAn Gene Third Party Clinical Testing Product Portfolio
- 12.14.5 DaAn Gene Recent Developments
- 12.15 Berry Genomics
- 12.15.1 Berry Genomics Company Information
- 12.15.2 Berry Genomics Business Overview
- 12.15.3 Berry Genomics Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.15.4 Berry Genomics Third Party Clinical Testing Product Portfolio
- 12.15.5 Berry Genomics Recent Developments
- 12.16 Frontage Holdings
- 12.16.1 Frontage Holdings Company Information
- 12.16.2 Frontage Holdings Business Overview
- 12.16.3 Frontage Holdings Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.16.4 Frontage Holdings Third Party Clinical Testing Product Portfolio
- 12.16.5 Frontage Holdings Recent Developments
- 12.17 Centre Testing International
- 12.17.1 Centre Testing International Company Information
- 12.17.2 Centre Testing International Business Overview
- 12.17.3 Centre Testing International Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.17.4 Centre Testing International Third Party Clinical Testing Product Portfolio
- 12.17.5 Centre Testing International Recent Developments
- 12.18 Shanghai Labway Clinical Laboratory
- 12.18.1 Shanghai Labway Clinical Laboratory Company Information
- 12.18.2 Shanghai Labway Clinical Laboratory Business Overview
- 12.18.3 Shanghai Labway Clinical Laboratory Revenue in Third Party Clinical Testing Business (2021-2026)
- 12.18.4 Shanghai Labway Clinical Laboratory Third Party Clinical Testing Product Portfolio
- 12.18.5 Shanghai Labway Clinical Laboratory Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst